Silas Inman

Socioeconomic factors significantly impact access to allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia, with certain groups less likely to receive this potentially lifesaving treatment.

Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.

The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma.

The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.

The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1-fusion-positive non–small cell lung cancer, including in those treated with other next-generation TKIs.

In a phase 3 trial, BVd demonstrated a substantial improvement in progression-free survival compared with DVd for patients with relapsed/refractory multiple myeloma.

Adding atezolizumab to bevacizumab plus chemotherapy did not derive benefit in recurrent ovarian cancer.

By dramatically reducing the risk of disease progression in patients with stage III melanoma neoadjuvant nivolumab plus ipilimumab emerges as a new standard of care in this setting.

Inavolisib combined with palbociclib and fulvestrant improved results for patients with HER2-negative, hormone receptor–positive, PIK3CA-mutated advanced or metastatic breast cancer.

Protocol amendment with sacituzumab govitecan shows promising responses, but questions remain for the use of the therapy in patients with bladder cancer.

Dose reductions of the GPRC5D/CD3 bispecific antibody talquetamab effectively improved on-target adverse events while sustaining high response rates for patients with relapsed/refractory multiple myeloma.

The use of the experimental navitoclax in combination with ruxolitinib produced impactful results for patients with myelofibrosis.

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

CD19-direct CAR T-cell therapies and the CD20-targeted bispecific antibodies both represent a viable treatment choice for patents with relapsed/refractory follicular lymphoma.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.

Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.

Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

News from KEYNOTE-671 in early-stage non–small cell lung cancer provides more evidence to support the FDA approval application for perioperative pembrolizumab.

The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.

Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.

Findings from the phase 2 HCRN GU 16-257 trial may help advance a more personalized approach to the management of muscle-invasive bladder cancer.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.

In the phase 3 TRANSFORM study, lisocabtagene maraleucel bested standard of care as treatment of patients with high-risk relapsed/refractory large B-cell lymphoma.

Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.